source
- Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decisionVertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…
- Genetic Testing Helps Refine Kidney Disease Trial Design, Says Natera ExpertIn a sponsored episode of The Top Line, Dr. Ronen Schneider, Natera's medical director of renal genetics, explains how genotype‑defined kidney disease data can improve clinical trial design. He not…